School of Medicine
Showing 1-10 of 52 Results
Saul A. Rosenberg, MD, Professor of Lymphoma
Current Research and Scholarly Interests Clinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.
The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.
Instructor, Medicine - Oncology
Current Research and Scholarly Interests I am an Instructor of Medicine in Oncology at Stanford. Since finishing the clinical component of my oncology fellowship, my clinical and research focus has been on breast cancer; my dedication to breast cancer care and research continues to grow as I become more fully immersed in this incredibly rewarding field.
I conduct research using an innovative breast cancer database that links patient medical records with cancer registry and genomic data. I am currently using this database to investigate the link between immune-mediated markers and survival in triple-negative breast cancer patients.
Furthermore, I have worked on a phase II clinical trial addressing the important question of whether single-agent PARP inhibitor therapy has anti-cancer activity in advanced BRCA wildtype, HER2-negative breast cancer patients with homologous recombination deficiency. I am co-principal investigator of this trial, and the recipient of a three-year Susan G. Komen Postdoctoral Fellowship Award surrounding this project.
Ash A. Alizadeh, MD/PhD
Assistant Professor of Medicine (Oncology)
Current Research and Scholarly Interests My research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.
Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.
Douglas W. Blayney
Professor of Medicine (Oncology) at the Stanford University Medical Center
Current Research and Scholarly Interests Improving the quality of cancer care at Stanford, in our network of care, and nationally
Robert W. Carlson
Professor of Medicine (Oncology and General Internal Medicine/Medical Informatics) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly Interests Clinical investigations in breast cancer include institutional and NSABP studies of chemoprevention, adjuvant therapy, psychosocial interventions, treatment of metastatic disease, methods of decreasing anthracycline cardiotoxicity, and modulation of multidrug resistance. Research in meta-analysis includes the performance of meta-analysis in a wide variety of settings in cancer treatment by the international Meta-Analysis Group in Cancer.
Professor of Medicine (Oncology) and of Biochemistry
Current Research and Scholarly Interests Our laboratory focuses on understanding how cells respond to DNA damage. Our research currently involves areas that interact with each other: repair of radiation damage, and transcriptional responses to DNA damage.
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head and Neck Surgery at the Stanford University Medical Center
Current Research and Scholarly Interests Multi- modality treatment of Head and Neck Cancer
Phase 1 clinical trials
Assistant Professor of Medicine (Oncology) and of Genetics
Current Research and Scholarly Interests The Curtis laboratory is focused on the development and application of innovative experimental, computational, and analytical approaches to improve the diagnosis, treatment, and early detection of cancer.
Alice C. Fan
Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center
Current Research and Scholarly Interests Dr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.